Möchten Sie immer auf dem neuesten Stand bleiben?

Austin, United States, July 01, 2026 (GLOBE NEWSWIRE) -- According to SNS Insider, The Multi-Cancer Early Detection Market was valued at USD 1.47 Billion in 2025 and is projected to reach USD 7.04...

60 Degrees Pharma reports DSMB recommends continuing the B-FREE Phase 2 chronic babesiosis study after finding no safety concerns.

Vivos’ Vida® Appliance Shows Statistically Significant Improvement in Insomnia Severity in 100% of Study Participants

Austin, United States, June 30, 2026 (GLOBE NEWSWIRE) -- According to SNS Insider, the Spatial Genomics and Transcriptomics Market was valued at USD 0.60 billion in 2025 and is projected to reach...

FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)...

Austin, TX, USA, June 29, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “Hematologic Malignancies Testing Market Size, Trends and Insights By Product...

SOUTH SAN FRANCISCO, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...

BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for...

4FRONT-2 global enrollment completed approximately 4 months ahead of initial projections4FRONT-2 over-enrolled (anticipated N>500), with final patient randomization expected in Q3 2026, reflecting...

HORIZON is a potentially pivotal, randomized, double-blind, placebo-controlled Phase 2 study evaluating TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 5.6 mg as a first-line monotherapy in adults...